Akpunonu 1995.

Methods	Multicentre, randomised, double‐blind, placebo‐controlled, parallel‐group. Single dose to treat single attack. Medication administered when migraine headache pain was of moderate or severe intensity Assessments by stopwatch and at discharge from emergency department (time not reported and may vary between participants) Rescue medication (excluding ergot derivatives) available after 90 minutes if headache relief not achieved Each participant provided with an open‐label 100 mg sumatriptan tablet to treat recurrence over the 24 h period after discharge
Participants	Aged 18 years or older, meeting IHS criteria for migraine (1988) with aura. At least 1‐year history of migraine. Participants with a frequency of tension headache of at least 15 days per month were excluded No concurrent use of monoamine oxidase inhibitors, lithium, or selective 5‐HT reuptake inhibitors No use of ergotamine within 24 h of study drug administration N = 136 Breakdown of participants by gender not reported Mean age not reported 100% with aura
Interventions	Sumatriptan 6 mg, n = 88 Placebo, n = 48
Outcomes	Adverse events
Notes	Oxford Quality Score: R1, DB1, W1. Total = 3.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not reported
Study size	High risk	Treatment group 50 to 200 participants, placebo group < 50 participants